As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. MRNA, -0.53% on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases.
With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, “we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,” Moderna Chief Executive Stephane Bancel said in a statement. “We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,” Mock said, “and I think that’s what the data is showing us right now.”
Moderna’s next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV.